Objectives: Escherichia coli (E. coli)-induced urinary tract infection (UTI) is very common infection associated with frequent use of antibiotics and increase in the global antibiotic re-sistances. We aimed to determine the susceptibility profile of Extended-Spectrum β -lactamase (ESBL) - producing E. coli isolated from the urinary samples to Fosfomycin and other antibiotics. Methods: The study retrospectively analyzed the clinical urine samples with ESBL-producing E. coli isolates; obtained from Jan 2018 to December 2019. We collected and analyzed all the data of the E. coli urinary isolates, and their antibiotic susceptibility pattern. Results: The study included 3044 E. coli isolates during the 2 years; 50.5% in 2018, and 49.5% in 2019; 38% (1161 isolates) were EBSL E. coli, and 0.7% (21 isolates) were Carbapenem-resistant Enterobacteriaceae (CRE). There were 1161 (38%) isolates with ESBL -producing E.coli, 51% isolated in 2018, and 49% isolated in 2019. The antibiotic susceptibility of ESBL-producing E. coli during the study period showed susceptibility to Trimethoprim/sulfamethoxazole (TMP/SMX) in 46% of isolates (50% in 2018, dropped to 42% in 2019), to Ciprofloxacin in 49% of isolates (49.5% in 2018, dropped to 48% in 2019), to Nitrofurantoin in 94% of isolates (94 in 2018, dropped to 89% in 2019), and to Fosfomycin in 97.5% of isolates (99% in 2018 dropped to 96% in 2019). Conclusions: ESBL -producing E. coli is an important cause of UTI in Bahrain. Fosfomycin is a very effective oral antimicrobial that still retains high efficacy against ESBL -producing E. coli, which helps to decrease the need for parenteral therapy, and consequently hospitalization.

Objectives: Escherichia coli (E. coli)-induced urinary tract infection (UTI) is very common infection associated with frequent use of antibiotics and increase in the global antibiotic re-sistances. We aimed to determine the susceptibility profile of Extended-Spectrum β -lactamase (ESBL) - producing ...